29 research outputs found
The Role of RANK-Ligand Inhibition in Cancer: The Story of Denosumab
The bone is a very common site of metastasis in patients with advanced cancer. Skeletal metastases are most common in breast and prostate cancer, but virtually any advanced cancer may disseminate to the bone. On the basis of recent advances in the understanding of bone remodeling processes, denosumab, a fully human monoclonal antibody against RANK-L, has been developed. Phase III clinical trials have demonstrated that denosumab is well tolerated and effective in the treatment of bone loss and prevention of skeletal-related events in patients with bone metastases
Analysis of micronucleated cells by flow cytometry. 2. Evaluating the accuracy of high-speed scoring
analysis of micronucleated cells by flow cytometry. 3. Advanced technology for detecting clastogenic activity
Analysis of micronucleated cells by flow cytometry. 1. Achieving high resolution with a malaria model
Intracellular Catabolism of an Antibody Drug Conjugate with a Non-Cleavable Linker
Abstract words: 56 Introduction words: 78